Stockreport

Design Therapeutics Maps H2 Data Readouts for RESTORE-FA, FECD Biomarker Study and DM1 Program [Yahoo! Finance]

Design Therapeutics, Inc.  (DSGN) 
PDF protein, including muscle biopsy) after 12 weeks of dosing, with topline data expected in the second half of the year Design is running an exploratory FECD Phase 2 bio [Read more]